Beaumont Health is excited to announce our involvement in the search for an effective vaccine for the COVID-19 coronavirus.
The vaccine that Beaumont will be testing is called AZD1222. It is expected that 40,000 people will be enrolled in this study across multiple countries, and Beaumont is looking to include hundreds of participants locally. This study will begin in November
2020 and participants will be followed for two years.
The study is called Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults.
Each eligible and enrolled participant will undergo two doses of the vaccine one month apart and will be followed periodically throughout the study. All interested individuals must be 18 years or older and meet an established set of inclusion criteria
including the following: